Poradosu Enrique 4
4 · Nuvectis Pharma, Inc. · Filed Feb 8, 2022
Insider Transaction Report
Form 4
Poradosu Enrique
Chief Science & Business Off
Transactions
- Purchase
Common Stock, par value $0.00001
2022-02-04$3.35/sh+3,800$12,730→ 1,196,849 total - Purchase
Common Stock, par value $0.00001
2022-02-07$3.88/sh+800$3,104→ 1,197,649 total
Footnotes (4)
- [F1]Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.25 to $3.43. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Includes 48,399 shares of restricted stock.
- [F3]Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.45 to $3.98. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F4]Includes 48,399 shares of restricted stock.